Tilray Brands, Inc. (TLRY.TO)

Negative net income growth while Drug Manufacturers - Specialty & Generic median is -9.15%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.

D&A growth of 0.26% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.

Deferred tax growth of 101.23% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would see a difference that might matter for future cash flow if significant.

SBC declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.

Working capital is shrinking yoy while Drug Manufacturers - Specialty & Generic median is -72.63%. Seth Klarman would see an advantage if sales remain robust.

AR growth of 80.67% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or more relaxed credit if revenue is not matching it.

Inventory shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a working capital edge if sales hold up.

AP shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.

Other WC usage shrinks yoy while Drug Manufacturers - Specialty & Generic median is -67.69%. Seth Klarman would see an advantage if top-line is stable or growing.

Other non-cash items dropping yoy while Drug Manufacturers - Specialty & Generic median is -47.15%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.

Negative CFO growth while Drug Manufacturers - Specialty & Generic median is -51.02%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.

CapEx growth of 28.46% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.

Acquisition spending declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note reduced M&A risk if growth continues organically.

Investment purchases shrink yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a short-term cash advantage if no high-return opportunities are missed.

We liquidate less yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a firm-specific hold strategy unless missed gains exist.

We reduce “other investing” yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a potential advantage in preserving cash if top-line growth is not harmed.

Reduced investing yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.

Debt repayment yoy declines while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.

Issuance growth of 671.23% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or acquisitions financed by new shares.

No Data available this quarter, please select a different quarter.